Cargando…
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment
Background. Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. Purpose. To update national standards for management of HCV-HIV coinfected adults in the Canadian context with evolving evidence for and acc...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947683/ https://www.ncbi.nlm.nih.gov/pubmed/27471521 http://dx.doi.org/10.1155/2016/4385643 |
_version_ | 1782443209425682432 |
---|---|
author | Hull, Mark Shafran, Stephen Wong, Alex Tseng, Alice Giguère, Pierre Barrett, Lisa Haider, Shariq Conway, Brian Klein, Marina Cooper, Curtis |
author_facet | Hull, Mark Shafran, Stephen Wong, Alex Tseng, Alice Giguère, Pierre Barrett, Lisa Haider, Shariq Conway, Brian Klein, Marina Cooper, Curtis |
author_sort | Hull, Mark |
collection | PubMed |
description | Background. Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. Purpose. To update national standards for management of HCV-HIV coinfected adults in the Canadian context with evolving evidence for and accessibility of effective and tolerable DAA therapies. The document addresses patient workup and treatment preparation, antiviral recommendations overall and in specific populations, and drug-drug interactions. Methods. A standing working group with HIV-HCV expertise was convened by The Canadian Institute of Health Research HIV Trials Network to review recently published HCV antiviral data and update Canadian HIV-HCV Coinfection Guidelines. Results. The gap in sustained virologic response between HCV monoinfection and HIV-HCV coinfection has been eliminated with newer HCV antiviral regimens. All coinfected individuals should be assessed for interferon-free, Direct Acting Antiviral HCV therapy. Regimens vary in content, duration, and success based largely on genotype. Reimbursement restrictions forcing the use of pegylated interferon is not acceptable if optimal patient care is to be provided. Discussion. Recommendations may not supersede individual clinical judgement. Treatment advances published since December 2015 are not considered in this document. |
format | Online Article Text |
id | pubmed-4947683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-49476832016-07-28 CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment Hull, Mark Shafran, Stephen Wong, Alex Tseng, Alice Giguère, Pierre Barrett, Lisa Haider, Shariq Conway, Brian Klein, Marina Cooper, Curtis Can J Infect Dis Med Microbiol Special Article Background. Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. Purpose. To update national standards for management of HCV-HIV coinfected adults in the Canadian context with evolving evidence for and accessibility of effective and tolerable DAA therapies. The document addresses patient workup and treatment preparation, antiviral recommendations overall and in specific populations, and drug-drug interactions. Methods. A standing working group with HIV-HCV expertise was convened by The Canadian Institute of Health Research HIV Trials Network to review recently published HCV antiviral data and update Canadian HIV-HCV Coinfection Guidelines. Results. The gap in sustained virologic response between HCV monoinfection and HIV-HCV coinfection has been eliminated with newer HCV antiviral regimens. All coinfected individuals should be assessed for interferon-free, Direct Acting Antiviral HCV therapy. Regimens vary in content, duration, and success based largely on genotype. Reimbursement restrictions forcing the use of pegylated interferon is not acceptable if optimal patient care is to be provided. Discussion. Recommendations may not supersede individual clinical judgement. Treatment advances published since December 2015 are not considered in this document. Hindawi Publishing Corporation 2016 2016-07-04 /pmc/articles/PMC4947683/ /pubmed/27471521 http://dx.doi.org/10.1155/2016/4385643 Text en Copyright © 2016 Mark Hull et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Article Hull, Mark Shafran, Stephen Wong, Alex Tseng, Alice Giguère, Pierre Barrett, Lisa Haider, Shariq Conway, Brian Klein, Marina Cooper, Curtis CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title_full | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title_fullStr | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title_full_unstemmed | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title_short | CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment |
title_sort | cihr canadian hiv trials network coinfection and concurrent diseases core research group: 2016 updated canadian hiv/hepatitis c adult guidelines for management and treatment |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947683/ https://www.ncbi.nlm.nih.gov/pubmed/27471521 http://dx.doi.org/10.1155/2016/4385643 |
work_keys_str_mv | AT hullmark cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT shafranstephen cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT wongalex cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT tsengalice cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT giguerepierre cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT barrettlisa cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT haidershariq cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT conwaybrian cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT kleinmarina cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment AT coopercurtis cihrcanadianhivtrialsnetworkcoinfectionandconcurrentdiseasescoreresearchgroup2016updatedcanadianhivhepatitiscadultguidelinesformanagementandtreatment |